LLBO Stock Overview
Operates as a medical technology company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Lifeline Biotechnologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.004 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | -50.00% |
| 3 Month Change | -66.67% |
| 1 Year Change | 9,900.00% |
| 3 Year Change | -90.00% |
| 5 Year Change | -90.91% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| LLBO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | 0.2% |
| 1Y | 9,900.0% | 12.5% | 22.0% |
Return vs Industry: LLBO exceeded the US Medical Equipment industry which returned 12.5% over the past year.
Return vs Market: LLBO exceeded the US Market which returned 22% over the past year.
Price Volatility
| LLBO volatility | |
|---|---|
| LLBO Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine LLBO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | n/a | Jim Holmes | www.lbti.co |
Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women.
Lifeline Biotechnologies, Inc. Fundamentals Summary
| LLBO fundamental statistics | |
|---|---|
| Market cap | US$434.89k |
| Earnings (TTM) | -US$574.27k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs LLBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLBO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$574.27k |
| Earnings | -US$574.27k |
Last Reported Earnings
Dec 31, 2009
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did LLBO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/08 03:57 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2009/12/31 |
| Annual Earnings | 2009/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lifeline Biotechnologies, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.